Consensus Jazz Pharmaceuticals plc

Stocks

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-26 EDT			5-day change	1st Jan Change
205.70 ^USD	-3.88%		-1.31%	+21.00%

10-26	Jazz Pharmaceuticals Expects $755 Million Charge to Impact Q3 Earnings	MT
10-23	Jazz Pharmaceuticals Plc Announces Updated Overall Survival Results From Phase 3 HERIZON-GEA-01 Trial Evaluating Ziihera In Combination With Chemotherapy	CI

Evolution of the Average Target: Jazz Pharmaceuticals plc

Evolution of the Target Price: Jazz Pharmaceuticals plc

Changes in Analyst Recommendations: Jazz Pharmaceuticals plc

9af42e1750e774e1ed51ad42034d.-3mqG4JvrfefZ3NgCGg6dLqEhpNqsKuUUOxYvyDB05M.1hrDRLYszrzRKBRYODoXDNfH0dIn3JrONLQN6k2Fnca0IMJY8RjMo-sjPg~9e845dc3bd997ebe42c2fe2f2ac179fe

Analysts' recommendations: Jazz Pharmaceuticals plc

10-09	BofA Securities Adjusts Jazz Pharmaceuticals Price Target to $313 From $307, Maintains Buy Rating	MT
10-08	RBC Trims Price Target on Jazz Pharmaceuticals to $296 From $299, Keeps Outperform Rating	MT
09-30	Citigroup Initiates Jazz Pharmaceuticals at Buy With $325 Price Target	MT
09-11	Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says	MT
09-11	UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating	MT
09-11	Analyst recommendations: Hims & Hers, Adobe, MongoDB…
08-28	Jazz Pharmaceuticals Shares May Have Room for Further Appreciation, RBC Says	MT
08-28	RBC Raises Price Target on Jazz Pharmaceuticals to $299 From $277, Keeps Outperform Rating	MT
08-26	U.S. research roundup- Intuit, MongoDB, Zscaler	RE
08-26	Deutsche Bank Adjusts Jazz Pharmaceuticals Price Target to $300 From $287, Maintains Buy Rating	MT
08-26	RBC Adjusts Price Target on Jazz Pharmaceuticals Public to $277 From $273, Maintains Outperform Rating	MT
08-11	Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says	MT
08-11	Morgan Stanley Adjusts Jazz Pharmaceuticals PT to $283 From $280, Maintains Overweight Rating	MT
08-05	UBS Adjusts Jazz Pharmaceuticals Price Target to $315 From $307, Maintains Buy Rating	MT
08-04	Jazz Pharmaceuticals Q2 Results Exceeded Expectations, With Growth Across Portfolio, RBC Says	MT
08-04	Jazz Pharmaceuticals Delivers Strong Q2, Xywav Drives Higher Guidance, Morgan Stanley Says	MT
08-04	RBC Capital Adjusts Price Target on Jazz Pharmaceuticals to $273 From $258, Maintains Outperform Rating	MT
08-04	Analyst recommendations: Walmart, Palantir Technologies, Cigna, Marriott International, Bank of New York Mellon Corporation...
08-04	Deutsche Bank Lifts Jazz Pharmaceuticals Price Target to $287 From $270, Maintains Buy Rating	MT
08-04	Morgan Stanley Adjusts PT on Jazz Pharmaceuticals to $280 From $245, Maintains Overweight Rating	MT
07-31	Jazz Pharmaceuticals Has Several Growth Options Beyond Marketed Drugs, RBC Says	MT
07-17	Canaccord Genuity Initiates Coverage on Jazz Pharmaceuticals With Buy Rating, $290 Price Target	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-09	Deutsche Bank Adjusts Jazz Pharmaceuticals PT to $270 From $250, Maintains Buy Rating	MT
07-02	Jazz Pharmaceuticals Investors Eye Ziihera Launch in GEA as Key Driver, UBS Says	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	JAZZ PHARMACEUTICALS PLC					+43.06%
	ELI LILLY AND COMPANY					+4.27%
	JOHNSON & JOHNSON					+4.92%
	ABBVIE INC.					-0.68%
	ROCHE HOLDING AG					-2.56%
	MERCK & CO., INC.					+13.62%
	NOVARTIS AG					-2.85%
	ASTRAZENECA PLC					+22.47%
	AMGEN INC.					-10.64%
	GILEAD SCIENCES, INC.					+0.95%
	Average					+7.26%
	Weighted average by Cap.					+3.67%